Introduction Post-ERCP pancreatitis (PEP) remains one of the most common and serious complications of Endoscopic Retrograde Cholangiopancreatography. Rectal NSAIDs such as Indomethacin and Diclofenac are strongly recommended for PEP prevention.
Introduction
Post-ERCP pancreatitis (PEP) remains one of the most common and serious complications of Endoscopic Retrograde Cholangiopancreatography. Rectal NSAIDs such as Indomethacin and Diclofenac are strongly recommended for PEP prevention. However, concerns about renal safety—especially in elderly patients and those with chronic kidney disease—have limited their widespread use in clinical practice.
This large multicenter prospective study evaluates whether a single peri-procedural dose of NSAIDs truly increases the risk of kidney injury, addressing an important clinical hesitation.
Problem Statement
Despite strong evidence supporting NSAIDs in reducing PEP, many clinicians avoid their use due to fear of acute kidney injury (AKI) or acute kidney disease (AKD). Current guidelines often recommend caution or avoidance in patients perceived to be at higher renal risk.
This creates a clinical dilemma:
👉 Should we compromise effective PEP prevention due to theoretical renal risks, or is this concern overstated?
Summary
In a large cohort of over 11,000 patients undergoing ERCP, approximately half received a single dose of rectal NSAIDs. The study found:
No significant association between NSAID use and AKI or AKD
Low absolute rates of kidney injury (0.5%–0.8%), even in high-risk groups
Consistent findings across:
Elderly patients
Patients with pre-existing chronic kidney disease
Propensity-matched analysis
Importantly, NSAIDs were also not associated with increased bleeding or other major adverse events.
These findings suggest that single-dose NSAIDs are safe from a renal standpoint in the ERCP setting, challenging the routine avoidance of these drugs.
Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...
Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...
Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...
Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...
Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.